These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16212127)

  • 1. Measles in Saudi Arabia: from control to elimination.
    Khalil MK; Al-Mazrou YY; AlHowasi MN; Al-Jeffri M
    Ann Saudi Med; 2005; 25(4):324-8. PubMed ID: 16212127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles immunization: early two-doses policy experience.
    al-Mazrou YY; al-Jeffri M; Ahmed OM; Aziz KM; Mishkas AH
    J Trop Pediatr; 1999 Apr; 45(2):98-104. PubMed ID: 10341504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles immunization in Saudi Arabia: the need for change.
    Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS
    East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies.
    Hennessey KA; Ion-Nedelcu N; Craciun MD; Toma F; Wattigney W; Strebel PM
    Am J Epidemiol; 1999 Dec; 150(11):1250-7. PubMed ID: 10588086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.
    Wood JG; Gidding HF; Heywood A; Macartney K; McIntyre PB; Macintyre CR
    Vaccine; 2009 Jan; 27(2):313-8. PubMed ID: 18977272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles outbreak in Qassim, Saudi Arabia 2007: epidemiology and evaluation of outbreak response.
    Jahan S; Al Saigul AM; Abu Baker MA; Alataya AO; Hamed SA
    J Public Health (Oxf); 2008 Dec; 30(4):384-90. PubMed ID: 18716046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh.
    Uddin MJ; Adhikary G; Ali MW; Ahmed S; Shamsuzzaman M; Odell C; Hashiguchi L; Lim SS; Alam N
    BMC Infect Dis; 2016 Aug; 16():411. PubMed ID: 27519586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles control in developing and developed countries: the case for a two-dose policy.
    Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
    Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles vaccine coverage and series completion among children 0-8 years of age in Tianjin, China.
    Montgomery JP; Zhang Y; Carlson B; Ewing S; Wang X; Boulton ML
    Pediatr Infect Dis J; 2015 Mar; 34(3):289-95. PubMed ID: 25259932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles epidemiology and elimination strategies in Turkey.
    Güriş D; Bayazit Y; Ozdemirer U; Buyurgan V; Yalniz C; Toprak I; Aycan S
    J Infect Dis; 2003 May; 187 Suppl 1():S230-4. PubMed ID: 12721918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.
    Aaby P; Jensen TG; Hansen HL; Kristiansen H; Thårup J; Poulsen A; Sodemann M; Jakobsen M; Knudsen K; Clotilde da Silva M
    Lancet; 1988 Oct; 2(8615):809-11. PubMed ID: 2902263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroresponse to the second measles vaccine dose at school entry in Qassim province, Saudi Arabia.
    Khalil MK; Nadrah HM; Al Yahia OA; ElGhazali G
    East Mediterr Health J; 2011 Mar; 17(3):191-5. PubMed ID: 21735958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of Australia's measles control programme over the past decade.
    Gidding HF
    Epidemiol Infect; 2005 Feb; 133(1):99-105. PubMed ID: 15724716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age.
    De Serres G; Boulianne N; Defay F; Brousseau N; Benoît M; Lacoursière S; Guillemette F; Soto J; Ouakki M; Ward BJ; Skowronski DM
    Clin Infect Dis; 2012 Aug; 55(3):394-402. PubMed ID: 22543023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward measles elimination--Japan, 1999-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Sep; 57(38):1049-52. PubMed ID: 18818586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
    Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.